Open Access
Scientific Reports, volume 11, issue 1, publication number 21955
Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs
Ursula Wolf
1
,
Sandra Eckert
2, 3
,
Grit Walter
4, 5
,
Andreas Wienke
6
,
Sylva Bartel
7
,
Stefan K. Plontke
7
,
Christina Naumann
5
3
Pediatrics, Städtisches Klinikum Dessau, Dessau-Roßlau, Germany
|
4
Speech Therapist and Psychological Consultant, Practice for Speech and Language Therapy, Halle (Saale), Germany
|
5
Department of Geriatrics and Geriatric Day Clinic, Diakonie Hospital, Diakoniewerk Halle (Saale), Halle (Saale), Germany
|
Publication type: Journal Article
Publication date: 2021-11-09
Multidisciplinary
Abstract
Risk factors for oropharyngeal dysphagia (OD) in elderly patients are mainly central nervous system (CNS) and structural organic diseases or presbyphagia. We analysed the OD prevalence and association of OD with multimorbidity and polypharmacy using real-life data to complete this spectrum, with a focus on further and iatrogenic risk. This was a cross-sectional retrospective study based on a random sample of 200 patients admitted to a geriatric hospital. Data analysis included diagnoses, the detailed list of drugs, and an intense clinical investigation of swallowing according to Stanschus to screen for OD in each patient. The mean patient age was 84 ± 6.5 years. The prevalence of OD was 29.0%, without an effect of age, but a higher rate was found in men and in nursing home residents and an elevated risk of pneumonia. OD risk was slight in diabetes mellitus and COPD, and pronounced in CNS diseases. A relevant OD association was found, even after adjusting for CNS diseases, with antipsychotics, benzodiazepines, anti-Parkinson drugs, antidepressants, and antiepileptics. Further risk of OD was found with beta-blockers, alpha-blockers, opioids, antiemetics, antivertiginosa or antihistamines, metoclopramide, domperidone, anticholinergics, loop diuretics, urologics, and ophthalmics. From real-life data in patients with and without CNS diseases, we identified drug groups associated with a risk of aggravating/inducing OD. Restrictive indications for these drugs may be a preventative contribution, requiring implementation in dysphagia guidelines and an integrative dysphagia risk scale that considers all associated and cumulative medication risks in addition to diseases.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.